Loading company…
ToBio develops molecular diagnostic platforms and point-of-care companion diagnostics.
ToBio develops diagnostic platforms and molecular companion diagnostic technologies, including PCR equipment that can test thousands of targets and issue a report within 15 to 30 minutes. Founded in 2024, it is based in Wuhan, China, with R&D centers in Boston and Shanghai. It raised CNY 50 million in angel funding in January 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in